IRIS

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Porta, Camillo;
2018-01-01

Abstract

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
2018
NEW ENGLAND JOURNAL OF MEDICINE
2-s2.0-85045136401
Esperti anonimi
Inglese
Internazionale
STAMPA
378
14
1277
1290
14
29562145
Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Pyrroles; Quality of Life; Risk; Sunitinib; Survival Analysis; Survival Rate
sì
32
info:eu-repo/semantics/article
262
Motzer, Robert J; Tannir, Nizar M; Mcdermott, David F; Arén Frontera, Osvaldo; Melichar, Bohuslav; Choueiri, Toni K; Plimack, Elizabeth R; Barthélémy,...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1258666
Citazioni
  • ???jsp.display-item.citation.pmc??? 1816
  • Scopus 3820
  • ???jsp.display-item.citation.isi??? ND
social impact